Log in to search using one of your social media accounts:

 

TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) partial clinical hold reactive statement
Roche: Based on emerging safety data from clinical trials evaluating pembrolizumab in combination with either lenalidomide or pomalidomide in multiple myeloma, the FDA has requested that a Phase Ib and a Phase Ib/II TECENTRIQ study be placed on partial clinical hold. (Source: Roche Investor Update)
Source: Roche Investor Update - September 15, 2017 Category: Pharmaceuticals Source Type: news

Survival Benefit in Myeloma With Lenalidomide Maintenance After Transplant
Patients with newly diagnosed multiple myeloma treated with lenalidomide maintenance therapy after undergoing autologous stem-cell transplantation had significantly improved overall survival compared with observation or placebo. (Source: CancerNetwork)
Source: CancerNetwork - August 17, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Roswell Park-Led Analysis Shows Survival Benefit of Lenalidomide...
New research analysis published in JCO definitively shows an overall survival benefit from ongoing treatment with lenalidomide for patients with multiple myeloma who have already received bone marrow...(PRWeb August 15, 2017)Read the full story at http://www.prweb.com/releases/2017/08/prweb14605233.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 15, 2017 Category: Pharmaceuticals Source Type: news

Maintenance Lenalidomide Improves PFS in DLBCL (CME/CE)
(MedPage Today) -- No difference in OS compared with placebo after a median follow-up of 52 months (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 4, 2017 Category: Primary Care Source Type: news

Revlimid drives Celgene profit beat; raises EPS forecast
(Reuters) - Celgene Corp rode its flagship multiple myeloma drug Revlimid and a rebound in sales of Otezla for psoriasis to a modestly higher-than-expected second-quarter profit and raised its full-year earnings forecast on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - July 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Celgene to Pay $280 Million to Settle Off-label Marketing Case Celgene to Pay $280 Million to Settle Off-label Marketing Case
The U.S. Justice Department said on Tuesday that Celgene Corp had agreed to pay $280 million to settle a lawsuit that accused the company of promoting its cancer drugs Revlimid and Thalomid for off-label uses.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs
The lawsuit accused the pharmaceutical company of marketing Thalomid and Revlimid for unapproved use on a broader range of cancers. (Source: NYT Health)
Source: NYT Health - July 26, 2017 Category: Consumer Health News Authors: KATIE THOMAS Tags: Drugs (Pharmaceuticals) Suits and Litigation (Civil) Thalidomide (Drug) Celgene Corporation Whistle-Blowers Cancer Food and Drug Administration Source Type: news

FDA Halts Pembrolizumab Trials in Multiple Myeloma
The US Food and Drug Administration (FDA) placed a clinical hold on three trials of the PD-1 inhibitor pembrolizumab in combination with pomalidomide or lenalidomide for patients with multiple myeloma: KEYNOTE-183, KEYNOTE-185, and KEYNOTE-023. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Amgen ’s multiple myeloma drug shows positive outcome in Phase III trial
Amgen has reported a positive outcome from the Phase III clinical trial (ASPIRE) of Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) to treat relapsed multiple myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - July 13, 2017 Category: Pharmaceuticals Source Type: news

Second Phase 3 Study Shows KYPROLIS ® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Patients Treated With the KYPROLIS-Based Regimen Survived 7.9 Months Longer Than Patients on Lenalidomide and Dexamethasone KYPROLIS-Based Regimens Are the First and Only to Demonstrate Improved Overall Survival Versus Today's Standards of Care in Two Phase 3 Studies in Relapsed Multiple Myeloma THOUSAND OAKS, Calif., July 12, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint ...
Source: Amgen News Release - July 12, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Triplet Combo Active in Lenalidomide/Refractory Multiple Myeloma
Combining bendamustine, pomalidomide, and dexamethasone achieved a promising overall response rate in patients with heavily pretreated lenalidomide refractory multiple myeloma, according to the results of a phase I/II trial. (Source: CancerNetwork)
Source: CancerNetwork - June 20, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Triplet Combo Active in Lenalidomide-Refractory Multiple Myeloma
Combining bendamustine, pomalidomide, and dexamethasone achieved a promising overall response rate in patients with heavily pretreated lenalidomide refractory multiple myeloma, according to the results of a phase I/II trial. (Source: CancerNetwork)
Source: CancerNetwork - June 20, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

DARZALEX ® (daratumumab) Approved by the U.S. FDA in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Who Have Received At Least Two Prior Therapies
DARZALEX combination therapy offers new option for patients previously treated with two commonly used treatments (lenalidomide and a proteasome inhibitor) (Source: Johnson and Johnson)
Source: Johnson and Johnson - June 17, 2017 Category: Pharmaceuticals Source Type: news

Significant Toxicity, Infection Risk Associated With Elo-RVD in Myeloma
In patients with newly diagnosed multiple myeloma, elotuzumab plus bortezomib, lenalidomide, and dexamethasone was associated with significant toxicity and infections. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Multiple Myeloma News Source Type: news

Janssen reports positive results from two Phase III combination trials of Darzalex
Janssen Research& Development has reported positive results from the updated Phase III CASTOR and POLLUX clinical trials of Darzalex (daratumumab) combined with bortezomib and dexamethasone or lenalidomide and dexamethasone to treat patients with mu … (Source: Drug Development Technology)
Source: Drug Development Technology - June 5, 2017 Category: Pharmaceuticals Source Type: news

Outcomes and Impact of Age on Therapy for Multiple Myeloma Outcomes and Impact of Age on Therapy for Multiple Myeloma
Is lenalidomide with low-dose dexamethasone effective for stem-cell transplantation-ineligible patients of any age with newly diagnosed MM?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Maintenance Lenalidomide Delayed Progression After R-CHOP for DLBCL
Maintenance lenalidomide significantly prolonged progression-free survival in elderly patients with diffuse large B-cell lymphoma who responded to first-line R-CHOP. (Source: CancerNetwork)
Source: CancerNetwork - April 25, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

RVD Plus Transplantation Delayed Progression in Myeloma
Combined treatment with lenalidomide, bortezomib, and dexamethasone plus transplantation significantly delayed progression in patients with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - April 12, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

MUK Phase Ib trial to assess Reolysin + Imnovid / Revlimid combination to treat myeloma
Cancer charity Myeloma UK and biotechnolgy firm Oncolytics Biotech have commenced a Phase Ib MUK eleven trial of Reolysin (pelareorep) in combination with Imnovid (pomalidomide) or Revlimid (lenalidomide) to treat patients with relapsing myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - March 17, 2017 Category: Pharmaceuticals Source Type: news

Oncolytics Biotech(R) Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN(R) in Combination with Imnovid(R) or Revlimid(R) in Patients with Myeloma
CALGARY, March 16, 2017 -- (Healthcare Sales & Marketing Network) - Oncolytics Biotech® Inc. (Oncolytics or the Company) (ONC.TO) (ONCYF) today announced that cancer charity Myeloma UK launched MUK eleven, a first-of-its-kind immunotherapy trial that ... Biopharmaceuticals, Oncology Oncolytics Biotech, REOLYSIN, pelareorep, pomalidomide, Revlimid, myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 16, 2017 Category: Pharmaceuticals Source Type: news

Revlimid (Lenalidomide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 6, 2017 Category: Drugs & Pharmacology Source Type: news

' DaraLenDex' Combo Best for Relapsed/Refractory Multiple Myeloma'DaraLenDex' Combo Best for Relapsed/Refractory Multiple Myeloma
The combination of daratumumab, lenalidomide and dexamethasone (DaraLenDex) appears to offer the best outcomes in patients with relapsed and/or refractory multiple myeloma (MM), according to a network meta-analysis involving 18 treatment options.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 3, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA Approves Maintenance Lenalidomide for Multiple Myeloma
The FDA has expanded the approval of lenalidomide to include its use as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant. (Source: CancerNetwork)
Source: CancerNetwork - March 2, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Lenalidomide Approved for Myeloma Maintenance After HSCT Lenalidomide Approved for Myeloma Maintenance After HSCT
Lenalidomide (Revlimid) gets the first-ever FDA approval for use in myeloma as a maintenance therapy after autologous stem cell transplant.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 23, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Expands Indication for Revlimid (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT)
SUMMIT, N.J.--(BUSINESS WIRE) February 22,2017 -- Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for Revlimid (lenalidomide) 10 mg capsules to include use for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 22, 2017 Category: Drugs & Pharmacology Source Type: news

Bortezomib Triplet Improves Outcomes in Newly Diagnosed Multiple Myeloma
Adding bortezomib to lenalidomide and dexamethasone improved progression-free and overall survival in patients with newly diagnosed multiple myeloma who were not planned for immediate stem-cell transplant. (Source: CancerNetwork)
Source: CancerNetwork - January 18, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Frontline Triplet With Bortezomib: New Standard in Myeloma? Frontline Triplet With Bortezomib: New Standard in Myeloma?
Bortezomib added to lenalidomide plus dexamethasone significantly increased both progression-free and overall survival in multiple myeloma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 29, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Lenalidomide Maintenance Improves Survival in Poor Prognosis DLBCL
Lenalidomide maintenance significantly improves survival in patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT). (Source: CancerNetwork)
Source: CancerNetwork - December 14, 2016 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Conferences/ASH 2016 Leukemia & Lymphoma News Source Type: news

Myeloma XI ’s Phase III trial result shows increase in myeloma patient remission
Myeloma XI has reported that the Phase III trial conducted in myeloma has indicated a 95% increase in progression-free survival (PFS) in myeloma patients receiving lenalidomide maintenance treatment. (Source: Drug Development Technology)
Source: Drug Development Technology - December 8, 2016 Category: Pharmaceuticals Source Type: news

Maintenance Lenalidomide Prolongs PFS in High-Risk CLL Maintenance Lenalidomide Prolongs PFS in High-Risk CLL
High-risk patients with CLL who receive lenalidomide as maintenance therapy following response to induction therapy have longer PFS compared with placebo.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 4, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Moffitt Cancer Center study shows improved response rates in myelodysplastic syndromes patients treated with lenalidomide and epoetin alpha
(H. Lee Moffitt Cancer Center& Research Institute) Patients with myelodysplastic syndromes (MDS) suffer from a reduction in the number of different types of blood cells, including red blood cells leading to the development of anemia. Many patients with lower-risk MDS benefit from treatment with recombinant-erythropoietin (rHuEPO), which stimulates blood cell production. However, patients who become refractory to rHuEPO have few effective treatment options. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2016 Category: Cancer & Oncology Source Type: news

FDA Approves Daratumumab Combinations for Previously Treated Myeloma
The FDA has approved daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy. (Source: CancerNetwork)
Source: CancerNetwork - December 2, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
HORSHAM, Pa., Nov. 21, 2016 -- (Healthcare Sales & Marketing Network) -- Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone, or bort... Biopharmaceuticals, Oncology, FDA Janssen Biotech, DARZALEX, daratumumab, multiple myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 22, 2016 Category: Pharmaceuticals Source Type: news

Darzalex (daratumumab) Approved by FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
HORSHAM, PA, Nov. 21, 2016 – Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 21, 2016 Category: Drugs & Pharmacology Source Type: news

Daratumumab Combo Significantly Improved PFS for Relapsed Myeloma
Adding daratumumab to lenalidomide and dexamethasone significantly improved progression-free survival in patients with relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - October 5, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Positive Top-Line Phase 2b STORM Results Reported, with Plans for Development Path of Selexinor for the Treatment of Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced the initiation of the STORM study (Selinexor Treatment of Refractory Myeloma) on September 6, 2016. STORM is a multi-center, single-arm Phase 2 study of selinexor (KPT-330) in heavily-pretreated patients with quad-refractory multiple myeloma. Selinexor, the company's lead, novel, oral Selective Inhibitor of Nuclear Export / SINE ™ compound, will be evaluated in combination with low-dose dexamethasone in multiple myeloma patients whose disease was refractory to treatment with bortezomib (Velcade®), lenalidomide (Revlimid...
Source: International Myeloma Foundation - September 28, 2016 Category: Hematology Source Type: news

Positive Top-Line Phase 2b STORM Results Reported, with Plans for Development Path of Selinexor for the Treatment of Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced the initiation of the STORM study (Selinexor Treatment of Refractory Myeloma) on September 6, 2016. STORM is a multi-center, single-arm Phase 2 study of selinexor (KPT-330) in heavily-pretreated patients with quad-refractory multiple myeloma. Selinexor, the company's lead, novel, oral Selective Inhibitor of Nuclear Export / SINE ™ compound, will be evaluated in combination with low-dose dexamethasone in multiple myeloma patients whose disease was refractory to treatment with bortezomib (Velcade®), lenalidomide (Revlimid...
Source: International Myeloma Foundation - September 28, 2016 Category: Hematology Source Type: news

EMA grants positive opinion for Takeda ’s NINLARO to treat multiple myeloma in adult patients
European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending the conditional approval of Takeda Pharmaceutical's NINLAROTM (ixazomib) capsules in combination with lenalidomide and d… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 18, 2016 Category: Pharmaceuticals Source Type: news

Lenalidomide in Adult ATL Shows Further Promise
Use of lenalidomide monotherapy in patients with adult T-cell leukemia/lymphoma resulted in clinically meaningful antitumor activity, with 42% of phase II trial participants having objective responses. (Source: CancerNetwork)
Source: CancerNetwork - September 13, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

Adding Carfilzomib Improved Health-Related QoL for Multiple Myeloma Patients
The addition of carfilzomib to lenalidomide and dexamethasone improved health-related quality of life compared with treatment with lenalidomide/dexamethasone alone among patients with relapsed multiple myeloma enrolled in the ASPIRE trial. (Source: CancerNetwork)
Source: CancerNetwork - September 7, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Health Canada grants marketing approval for Takeda ’s multiple myeloma teatment
Health Canada has approved Japanese-based Takeda Pharmaceutical Company ’s Ninlaro (ixazomib) capsules, in combination with lenalidomide and dexamethasone, to treat patients with multiple myeloma (MM). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 9, 2016 Category: Pharmaceuticals Source Type: news

Health Canada grants marketing approval for Takeda ’s multiple myeloma treatment
Health Canada has approved Japanese-based Takeda Pharmaceutical Company ’s Ninlaro (ixazomib) capsules, in combination with lenalidomide and dexamethasone, to treat patients with multiple myeloma (MM). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 9, 2016 Category: Pharmaceuticals Source Type: news

Three-Drug Regimen Beneficial for High-Risk Cytogenetic Myeloma Subgroup
Treatment with carfilzomib, lenalidomide, and dexamethasone improved the poor prognosis associated with high-risk cytogenetic abnormalities of multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - August 4, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

MorphoSys reports positive safety run-in Phase II L-MIND trial results of MOR208 to treat DLBCL
German biotechnology firm MorphoSys has completed the safety run-in phase of its Phase II L-MIND trial of MOR208 combined with lenalidomide, to treat relapsed or refractory diffuse large B cell lymphoma (DLBCL). (Source: Drug Development Technology)
Source: Drug Development Technology - August 3, 2016 Category: Pharmaceuticals Source Type: news

Sales of flagship drug Revlimid drive Celgene profit; forecast raised
NEW YORK (Reuters) - Celgene Corp raised its 2016 profit forecast and exceeded expectations for second-quarter earnings on Thursday on the strength of its flagship multiple myeloma drug Revlimid and growth in newer medicines, sparking a 2 percent jump in its shares. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Revlimid Fails to Extend Survival in Lymphoma Study Revlimid Fails to Extend Survival in Lymphoma Study
Celgene Corp said on Monday that its flagship drug Revlimid (lenalidomide) failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Celgene drug fails to extend survival in lymphoma study
(Reuters) - Celgene Corp said on Monday that its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment. (Source: Reuters: Health)
Source: Reuters: Health - July 25, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Early Treatment of Smoldering Myeloma: Is It Time?Early Treatment of Smoldering Myeloma: Is It Time?
The combination lenalidomide and dexamethasone has been shown to delay the progression of smoldering multiple myeloma. So should this approach be used in clinical practice? Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 19, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Early Treatment of Smoldering Myeloma: Is It Time? Early Treatment of Smoldering Myeloma: Is It Time?
The combination lenalidomide and dexamethasone has been shown to delay the progression of smoldering multiple myeloma. So should this approach be used in clinical practice? Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 19, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
BOUDRY, Switzerland--(Healthcare Sales & Marketing Network)--Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (CELG) today announced that the European Commission (EC) has approved REVLIMID® (lenalidomide) for the trea... Biopharmaceuticals, Oncology, RegulatoryCelgene International Sàrl, REVLIMID, lenalidomide, mantle cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 15, 2016 Category: Pharmaceuticals Source Type: news